Guggenheim raised the firm’s price target on Abivax (ABVX) to $150 from $101 and keeps a Buy rating on the shares, which have also been designated as the analyst’s “Best Idea” after the analyst attended the UEGW conference in Berlin and also hosted an investor dinner with the company’s management team. There was “unanimous agreement” among the key opinion leaders that the use and adoption of obefazimod is likely to be broad from front-line to later-line usage, reports the analyst, who envision the drug becoming “the cornerstone oral treatment” for ulcerative colitis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax price target raised to $120 from $112 at BTIG
- Abivax’s Obefazimod: Promising Clinical Results and Market Potential Drive Buy Rating
- Abivax announces ABTECT 1, ABTECT 2 trials met primary endpoint
- Promising Phase 2b Results and Competitive Positioning Support Buy Rating for Abivax’s Obefazimod
- Abivax price target raised to $114 from $95 at Citizens JMP